<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="utf-8" />
<meta name="viewport" content="width=device-width, initial-scale=1" />
<title>Investment Memorandum — Multi-Service Medispa (2024 Normalized)</title>
<style>
  :root{
    --ink:#0f172a;            /* Slate-900 */
    --muted:#475569;          /* Slate-600 */
    --faint:#94a3b8;          /* Slate-400 */
    --accent:#0f766e;         /* Teal-700 */
    --accent-ink:#0b5c56;
    --bg:#ffffff;
    --rule:#e2e8f0;           /* Slate-200 */
  }
  @page{
    size: Letter;
    margin: 20mm 16mm 18mm 16mm;
  }
  @media print{
    .no-print{ display:none !important; }
    a[href^="http"]::after{ content:""; } /* suppress print URL tails */
    header, footer { position: fixed; left:0; right:0; }
    header { top: 8mm; }
    footer { bottom: 8mm; color: var(--muted); font-size: 10.5px; }
    .page-num:after { content: counter(page) " of " counter(pages); }
    .pb { page-break-before: always; }
    .pba { page-break-after: always; }
  }
  body{
    font: 12.4px/1.5 "Inter", system-ui, -apple-system, Segoe UI, Roboto, Arial, sans-serif;
    color: var(--ink);
    background: var(--bg);
    -webkit-font-smoothing: antialiased;
    margin: 0;
  }
  header{
    display: grid;
    grid-template-columns: 1fr auto;
    align-items: end;
    border-bottom: 1px solid var(--rule);
    padding-bottom: 8px;
    margin-bottom: 14px;
  }
  .brand{
    font-weight: 700;
    letter-spacing: .2px;
    color: var(--accent);
    font-size: 13.5px;
    text-transform: uppercase;
  }
  .doc-title{
    font-weight: 800;
    font-size: 18px;
    letter-spacing: .2px;
    color: var(--ink);
    margin: 2px 0 0 0;
  }
  .meta{
    text-align: right;
    color: var(--muted);
    font-size: 12px;
  }
  .grid{
    display: grid;
    grid-template-columns: 1fr 1fr;
    gap: 14px 18px;
  }
  h2{
    font-size: 13.8px;
    letter-spacing: .2px;
    color: var(--accent-ink);
    margin: 16px 0 6px 0;
    border-bottom: 1px solid var(--rule);
    padding-bottom: 4px;
  }
  h3{
    font-size: 12.6px;
    margin: 10px 0 6px 0;
    color: var(--ink);
  }
  p{ margin: 6px 0 8px 0; color: var(--ink); }
  .small{ color: var(--muted); font-size: 11px; }
  .lead{
    border-left: 3px solid var(--accent);
    padding: 8px 10px;
    background: linear-gradient(90deg, #f8fafc 0, transparent 100%);
    margin: 6px 0 10px 0;
  }
  .badge{
    display: inline-block; padding: 2px 8px; border-radius: 999px;
    background: #ecfeff; color: var(--accent-ink); border: 1px solid #99f6e4;
    font-weight: 600; font-size: 11px; letter-spacing: .2px; margin-right: 6px;
  }
  .kpi{
    display:flex; gap:10px; flex-wrap:wrap; margin-top:6px;
  }
  .kpi .pill{
    border:1px solid var(--rule); border-radius:10px; padding:8px 10px; min-width: 150px;
  }
  .pill .label{ color: var(--muted); font-size: 11px; margin-bottom: 2px; }
  .pill .value{ font-weight: 700; color: var(--ink); }
  ul{ margin: 6px 0 8px 18px; }
  li{ margin: 3px 0; }
  .table{
    width: 100%;
    border-collapse: collapse;
    margin: 6px 0 10px 0;
    font-variant-numeric: tabular-nums lining-nums;
  }
  .table th{
    text-align: left; color: var(--muted); font-weight: 600; font-size: 11.5px;
    border-bottom: 1px solid var(--rule); padding: 6px 6px 6px 0;
  }
  .table td{
    padding: 6px 6px 6px 0; border-bottom: 1px dashed #eef2f7;
  }
  .num{ text-align: right; }
  .callout{
    border:1px solid var(--rule); border-left:3px solid var(--accent);
    border-radius: 6px; padding: 8px 10px; background: #fbfdff;
    margin: 8px 0 10px 0;
  }
  .footer-note{ margin-top: 6px; color: var(--muted); font-size: 11px; }
  .cols-3{
    display:grid; grid-template-columns: repeat(3, 1fr); gap: 10px 16px;
  }
  .checklist li{ margin: 4px 0; }
  hr.sep{ border:0; border-top:1px solid var(--rule); margin: 10px 0; }
</style>
</head>
<body>

<header>
  <div>
    <div class="brand">CPP — Investment Committee</div>
    <div class="doc-title">Investment Memorandum — Multi-Service Medispa (2024 Normalized)</div>
    <div class="small">All figures in <strong>$000s</strong> unless noted.</div>
  </div>
  <div class="meta">
    <div><strong>From:</strong> Drew Williams (M&amp;A)</div>
    <div><strong>Date:</strong> July 28, 2025</div>
    <div><strong>Subject:</strong> IOI Recommendation — Single-Site Medispa</div>
  </div>
</header>

<main>

  <section>
    <h2>1) Executive Summary &amp; Recommendation</h2>
    <div class="lead">
      <span class="badge">Recommendation</span> Submit IOI at <strong>7.0× Adj. EBITDA</strong>, structured <strong>70% Cash / 30% Roll</strong>, contingent upon:
      <ul>
        <li><strong>QoE</strong> confirming Adjusted EBITDA = <strong>$688</strong>.</li>
        <li><strong>Verification of net debt &amp; debt-like items</strong> (price adjusted for net debt and NWC at close).</li>
      </ul>
    </div>

    <div class="kpi">
      <div class="pill"><div class="label">Enterprise Value (EV)</div><div class="value">$4,813</div></div>
      <div class="pill"><div class="label">Estimated Net Debt (inferred)</div><div class="value">$1,948</div></div>
      <div class="pill"><div class="label">Equity Value</div><div class="value">$2,865</div></div>
      <div class="pill"><div class="label">Proceeds (70/30)</div><div class="value">Cash $2,006 / Roll $860</div></div>
    </div>

    <p class="small"><em>Net debt inference basis:</em> reported interest expense <strong>$194.8</strong> at assumed 10% cost of debt ⇒ <strong>$1,948</strong>. Replaced by actual loan/lease schedules and payoff letters in diligence.</p>

    <p><strong>Rationale.</strong> Cash-pay revenue, ~70% GP, and recurring injectables support a mid-band multiple; single-site/provider concentration and device uptime risk keep me at <strong>7×</strong> (range 6–8×). 30% Roll aligns retention and near-term execution.</p>
  </section>

  <section class="grid">
    <div>
      <h2>2) Normalization to Adjusted EBITDA $688</h2>
      <table class="table" style="table-layout: fixed; width: 100%;">
        <colgroup>
          <col style="width: 70%;">
          <col style="width: 30%;">
        </colgroup>
        <thead>
          <tr>
            <th style="text-align: left;">Bridge (2024)</th>
            <th style="text-align: right;">Amount</th>
          </tr>
        </thead>
        <tbody>
          <tr><td>Revenue</td><td style="text-align: right;">$3,726</td></tr>
          <tr><td>Gross Profit (~70%)</td><td style="text-align: right;">$2,623</td></tr>
          <tr><td>Sales &amp; Marketing (normalized to 10% rev)</td><td style="text-align: right;">($373)</td></tr>
          <tr><td>Owner add-back (+$300)</td><td style="text-align: right;">+300</td></tr>
          <tr><td>Interest (reclass below EBITDA)</td><td style="text-align: right;">+195</td></tr>
          <tr><td>Depreciation (non-cash)</td><td style="text-align: right;">+135</td></tr>
          <tr><td><strong>Adjusted EBITDA</strong></td><td style="text-align: right;"><strong>$688</strong></td></tr>
        </tbody>
      </table>
      <div class="callout">
        <strong>Sanity checks.</strong> ND/EBITDA = <strong>2.8×</strong>; EBITDA/Interest ≈ <strong>3.5×</strong>. Marketing reset supports sustainable demand generation; owner add-back reflects only excess above post-close comp ladder.
      </div>
    </div>
    <div>
      <h2>3) Investment Analysis — Chain of Thought</h2>
      <h3>a) Concerns (what could break the case)</h3>
      <ul>
        <li>Seasonality; risk 10% S&amp;M insufficient to maintain lead flow.</li>
        <li>Device downtime &gt;10% for 30+ days.</li>
        <li>Key-provider dependency: injector churn &gt;15% in first 90 days.</li>
      </ul>
      <h3>b) Opportunities</h3>
      <ul>
        <li>Memberships &amp; pricing governance to lift LTV and revenue/hour.</li>
        <li>Injector productivity ladder (utilization, mix, scheduling discipline).</li>
      </ul>
      <h3>c) Adjustments</h3>
      <ul>
        <li>S&amp;M to 10% rev; owner +$300; remove one-offs; reclass interest; add back depreciation → <strong>$688</strong>.</li>
      </ul>
      <h3>d) Fair multiple</h3>
      <ul><li><strong>7.0×</strong> (band 6–8×) — cash-pay, ~70% GP, recurring mix vs single-site risk.</li></ul>
      <h3>e) Other methods</h3>
      <ul><li>EPV, simple DCF, comps/precedents bracket 6–8×; support 7× midpoint.</li></ul>
      <h3>f) Cash vs Equity split</h3>
      <ul><li>70/30 improves retention/alignment; preserves growth capex and leverage headroom.</li></ul>
      <h3>g) Owner compensation impact</h3>
      <ul><li>Keep market post-close comp; add back only the excess ($300). Producer continuity secured via employment + rollover.</li></ul>
    </div>
  </section>

  <section class="grid">
    <div>
      <h2>4) Valuation &amp; Offer (Completed) + Sensitivities</h2>
      <table class="table" style="table-layout: fixed; width: 100%;">
        <colgroup>
          <col style="width: 45%;">
          <col style="width: 18.33%;">
          <col style="width: 18.33%;">
          <col style="width: 18.33%;">
        </colgroup>
        <thead>
          <tr>
            <th style="text-align: left;">QoE × Multiple — <span class="small">Equity Value</span></th>
            <th style="text-align: center;">6×</th>
            <th style="text-align: center;">7× (base)</th>
            <th style="text-align: center;">8×</th>
          </tr>
        </thead>
        <tbody>
          <tr>
            <td>EBITDA −10% (619)</td>
            <td style="text-align: center;">1,767</td>
            <td style="text-align: center;">2,386</td>
            <td style="text-align: center;">3,006</td>
          </tr>
          <tr>
            <td>EBITDA Base (688)</td>
            <td style="text-align: center;">2,180</td>
            <td style="text-align: center;"><strong>2,865</strong></td>
            <td style="text-align: center;">3,556</td>
          </tr>
          <tr>
            <td>EBITDA +10% (757)</td>
            <td style="text-align: center;">2,593</td>
            <td style="text-align: center;">3,350</td>
            <td style="text-align: center;">4,106</td>
          </tr>
        </tbody>
      </table>
      <p class="small">Proceeds per cell: 70% Cash / 30% Roll (e.g., base 7× ≈ Cash $2,006 / Roll $860; rounded in deck to $2,006 / $860).</p>
      <div class="callout">
        <strong>Marketing sensitivity (no revenue response).</strong> ΔEquity per 1% S&amp;M = Multiple × (1% × Revenue). At 7×, ≈ <strong>$261</strong> (1% of $3,726 ≈ $37.3; ×7 ≈ $261).
      </div>
    </div>

    <div>
      <h2>5) Major Risks &amp; Mitigations</h2>
      <div class="cols-3">
        <div>
          <h3>Injector retention</h3>
          <ul class="checklist">
            <li>Rollover alignment (30%).</li>
            <li>Employment &amp; stay bonuses.</li>
            <li>Comp ladder; recruiting bench.</li>
          </ul>
        </div>
        <div>
          <h3>Device uptime / capex</h3>
          <ul class="checklist">
            <li>OEM SLAs; preventive maintenance.</li>
            <li>Capex reserve &amp; schedule.</li>
            <li>Downtime KPI cadence.</li>
          </ul>
        </div>
        <div>
          <h3>Competition &amp; pricing</h3>
          <ul class="checklist">
            <li>Pricing governance (floors/ceiling).</li>
            <li>Promo calendar; geo-targeting.</li>
            <li>Membership benefits (stickiness).</li>
          </ul>
        </div>
      </div>
      <h3>Regulatory/structural</h3>
      <ul class="checklist">
        <li>Transact via MSO where required.</li>
        <li>Confirm licensure, delegation protocols.</li>
        <li>Advertising/claims compliance.</li>
      </ul>
    </div>
  </section>

  <section class="grid">
    <div>
      <h2>6) Due Diligence Priorities (30–45 Days)</h2>
      <ul class="checklist">
        <li><strong>QoE &amp; revenue recognition</strong> — validate $688; seasonality; one-offs.</li>
        <li><strong>Debt &amp; debt-like</strong> — loan/lease schedules; payoff letters; gift cards/prepaids; fees/taxes; cash at close.</li>
        <li><strong>Working capital</strong> — NWC peg = LTM monthly average; purchase price adjustment.</li>
        <li><strong>Provider agreements</strong> — employment terms, non-competes, schedules; rollover intentions.</li>
        <li><strong>Device fleet</strong> — uptime logs; SLAs; near-term capex.</li>
        <li><strong>Marketing analytics</strong> — lead sources; CPL/CPA; cohort retention; membership penetration.</li>
      </ul>
      <p class="small">Each item closes a direct valuation risk: QoE → EBITDA; debt-like/NWC → equity; provider/device → run-rate stability.</p>
    </div>
    <div>
      <h2>7) Integration &amp; Value-Creation (Day 1 → Day 100)</h2>
      <h3>Day-1 readiness (go-live controls)</h3>
      <ul>
        <li>Payroll &amp; comp ladder; scheduling discipline; pricing governance.</li>
        <li>ROAS instrumentation; KPI baseline.</li>
      </ul>
      <h3>90-day goals</h3>
      <ul>
        <li>Provider/room utilization targets; membership attach-rate.</li>
        <li>Downtime KPI cadence; monthly GP→EBITDA bridge review.</li>
      </ul>
      <h3>People &amp; incentives</h3>
      <ul>
        <li>Finalize provider retention/stay bonuses.</li>
        <li>Stand up equity/bonus pool tied to productivity &amp; patient satisfaction.</li>
      </ul>
    </div>
  </section>

  <section>
    <h2>8) Proposed IOI Terms</h2>
    <table class="table">
      <tbody>
        <tr><td><strong>Valuation</strong></td><td>7.0× Adjusted EBITDA (base $688)</td></tr>
        <tr><td><strong>Consideration</strong></td><td>70% Cash / 30% Roll (sized off Equity at close)</td></tr>
        <tr><td><strong>Conditions</strong></td><td>QoE confirmation; verification of debt &amp; debt-like items; customary reps &amp; warranties</td></tr>
        <tr><td><strong>Exclusivity</strong></td><td>45 days for confirmatory diligence &amp; definitive documentation</td></tr>
        <tr><td><strong>Escrow</strong></td><td>TBD% to cover undisclosed liabilities</td></tr>
        <tr><td><strong>NWC Peg</strong></td><td>LTM monthly average; purchase price adjusted at close</td></tr>
      </tbody>
    </table>

    <hr class="sep" />

    <div class="small">
      <strong>Valuation triangulation.</strong> EPV (steady-state after maintenance capex), simple DCF, and comps/precedents collectively support the 6–8× bracket and my 7× anchor.
    </div>
  </section>

</main>

<footer>
  <div style="display:flex;justify-content:space-between;">
    <div>CPP &middot; Multi-Service Medispa &middot; July 28, 2025</div>
    <div>Page <span class="page-num"></span></div>
  </div>
</footer>

</body>
</html> 